US 10,889,642 B2
Treatment of fibrosis with interleukin-11 receptor alpha antibody
Stuart Alexander Cook, Singapore (SG); and Sebastian Schaefer, Singapore (SG)
Assigned to Singapore Health Services PTE LTD, Singapore (SG); and National University of Singapore, Singapore (SG)
Filed by Singapore Health Services PTE LTD., Singapore (SG); and National University of Singapore, Singapore (SG)
Filed on Aug. 21, 2018, as Appl. No. 16/106,047.
Application 15/988,463 is a division of application No. 15/381,622, filed on Dec. 16, 2016, granted, now 10,035,852.
Application 16/106,047 is a continuation of application No. 15/988,463, filed on May 24, 2018, granted, now 10,106,603.
Claims priority of application No. 1522186.4 (GB), filed on Dec. 16, 2015.
Prior Publication US 2018/0371077 A1, Dec. 27, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [C07K 14/5428 (2013.01); C07K 14/7155 (2013.01); C07K 16/2866 (2013.01); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/32 (2013.01); C07K 2319/43 (2013.01); C12N 2310/14 (2013.01)] 11 Claims
 
1. A method of treating a disease or condition characterised by fibrosis of the eye in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 receptor α (IL-11Rα) antibody which is capable of inhibiting Interleukin 11 (IL-11) mediated signaling.